vs
Side-by-side financial comparison of SS&C Technologies Holdings Inc (SSNC) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.6B, roughly 1.4× SS&C Technologies Holdings Inc). Zoetis runs the higher net margin — 25.3% vs 13.7%, a 11.5% gap on every dollar of revenue. On growth, SS&C Technologies Holdings Inc posted the faster year-over-year revenue change (8.8% vs 3.0%). Over the past eight quarters, SS&C Technologies Holdings Inc's revenue compounded faster (6.5% CAGR vs 4.4%).
SS&C Technologies Holdings, Inc. is an American multinational holding company headquartered in Windsor, Connecticut, that sells software and software as a service to the financial services industry. The company has offices in the Americas, Europe, Asia, Africa and Australia.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SSNC vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.4B |
| Net Profit | $226.1M | $603.0M |
| Gross Margin | 48.7% | 70.2% |
| Operating Margin | 24.2% | 31.9% |
| Net Margin | 13.7% | 25.3% |
| Revenue YoY | 8.8% | 3.0% |
| Net Profit YoY | 6.2% | 3.8% |
| EPS (diluted) | $0.91 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.7B | $2.4B | ||
| Q3 25 | $1.6B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.5B | $2.2B | ||
| Q4 24 | $1.5B | $2.3B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.5B | $2.4B |
| Q1 26 | $226.1M | — | ||
| Q4 25 | $193.1M | $603.0M | ||
| Q3 25 | $210.0M | $721.0M | ||
| Q2 25 | $180.8M | $718.0M | ||
| Q1 25 | $213.0M | $631.0M | ||
| Q4 24 | $248.2M | $581.0M | ||
| Q3 24 | $164.4M | $682.0M | ||
| Q2 24 | $190.3M | $624.0M |
| Q1 26 | 48.7% | — | ||
| Q4 25 | 47.8% | 70.2% | ||
| Q3 25 | 47.7% | 71.5% | ||
| Q2 25 | 48.0% | 73.6% | ||
| Q1 25 | 49.3% | 72.0% | ||
| Q4 24 | 49.3% | 69.5% | ||
| Q3 24 | 48.0% | 70.6% | ||
| Q2 24 | 48.1% | 71.7% |
| Q1 26 | 24.2% | — | ||
| Q4 25 | 22.3% | 31.9% | ||
| Q3 25 | 23.3% | 37.0% | ||
| Q2 25 | 22.4% | 36.7% | ||
| Q1 25 | 23.6% | 36.5% | ||
| Q4 24 | 23.4% | 31.6% | ||
| Q3 24 | 22.2% | 36.6% | ||
| Q2 24 | 22.6% | 33.0% |
| Q1 26 | 13.7% | — | ||
| Q4 25 | 11.7% | 25.3% | ||
| Q3 25 | 13.4% | 30.0% | ||
| Q2 25 | 11.8% | 29.2% | ||
| Q1 25 | 14.1% | 28.4% | ||
| Q4 24 | 16.2% | 25.1% | ||
| Q3 24 | 11.2% | 28.6% | ||
| Q2 24 | 13.1% | 26.4% |
| Q1 26 | $0.91 | — | ||
| Q4 25 | $0.76 | $1.37 | ||
| Q3 25 | $0.83 | $1.63 | ||
| Q2 25 | $0.72 | $1.61 | ||
| Q1 25 | $0.84 | $1.41 | ||
| Q4 24 | $0.98 | $1.29 | ||
| Q3 24 | $0.65 | $1.50 | ||
| Q2 24 | $0.75 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $420.9M | — |
| Total DebtLower is stronger | $7.4B | — |
| Stockholders' EquityBook value | $6.9B | $3.3B |
| Total Assets | $20.3B | $15.5B |
| Debt / EquityLower = less leverage | 1.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $420.9M | — | ||
| Q4 25 | $462.1M | — | ||
| Q3 25 | $388.3M | $2.1B | ||
| Q2 25 | $480.3M | $1.4B | ||
| Q1 25 | $515.0M | $1.7B | ||
| Q4 24 | $567.1M | $2.0B | ||
| Q3 24 | $694.7M | $1.7B | ||
| Q2 24 | $462.7M | $1.6B |
| Q1 26 | $7.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $3.3B | ||
| Q3 25 | $6.9B | $5.4B | ||
| Q2 25 | $6.9B | $5.0B | ||
| Q1 25 | $6.8B | $4.7B | ||
| Q4 24 | $6.5B | $4.8B | ||
| Q3 24 | $6.8B | $5.2B | ||
| Q2 24 | $6.4B | $5.0B |
| Q1 26 | $20.3B | — | ||
| Q4 25 | $20.7B | $15.5B | ||
| Q3 25 | $19.5B | $15.2B | ||
| Q2 25 | $19.0B | $14.5B | ||
| Q1 25 | $20.4B | $14.1B | ||
| Q4 24 | $19.0B | $14.2B | ||
| Q3 24 | $18.4B | $14.4B | ||
| Q2 24 | $16.9B | $14.2B |
| Q1 26 | 1.08× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $299.7M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | 0.0% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.33× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $299.7M | — | ||
| Q4 25 | $643.5M | $893.0M | ||
| Q3 25 | $456.2M | $938.0M | ||
| Q2 25 | $372.9M | $486.0M | ||
| Q1 25 | $272.2M | $587.0M | ||
| Q4 24 | $486.6M | $905.0M | ||
| Q3 24 | $336.6M | $951.0M | ||
| Q2 24 | $384.9M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $633.0M | $732.0M | ||
| Q3 25 | $421.5M | $805.0M | ||
| Q2 25 | $350.0M | $308.0M | ||
| Q1 25 | $259.5M | $438.0M | ||
| Q4 24 | $466.9M | $689.0M | ||
| Q3 24 | $310.7M | $784.0M | ||
| Q2 24 | $374.9M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 38.3% | 30.7% | ||
| Q3 25 | 26.9% | 33.5% | ||
| Q2 25 | 22.8% | 12.5% | ||
| Q1 25 | 17.1% | 19.7% | ||
| Q4 24 | 30.5% | 29.7% | ||
| Q3 24 | 21.2% | 32.8% | ||
| Q2 24 | 25.8% | 15.7% |
| Q1 26 | 0.0% | — | ||
| Q4 25 | 0.6% | 6.7% | ||
| Q3 25 | 2.2% | 5.5% | ||
| Q2 25 | 1.5% | 7.2% | ||
| Q1 25 | 0.8% | 6.7% | ||
| Q4 24 | 1.3% | 9.3% | ||
| Q3 24 | 1.8% | 7.0% | ||
| Q2 24 | 0.7% | 5.6% |
| Q1 26 | 1.33× | — | ||
| Q4 25 | 3.33× | 1.48× | ||
| Q3 25 | 2.17× | 1.30× | ||
| Q2 25 | 2.06× | 0.68× | ||
| Q1 25 | 1.28× | 0.93× | ||
| Q4 24 | 1.96× | 1.56× | ||
| Q3 24 | 2.05× | 1.39× | ||
| Q2 24 | 2.02× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSNC
| Technology-enabled services | $1.4B | 85% |
| License, maintenance and related | $239.8M | 15% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
